Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Xeris Biopharma Holdings, Inc. - Common Stock (NQ:XERS)

4.110 +0.030 (+0.74%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Xeris Biopharma Holdings, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Mid-Afternoon Market Update: Dow Jumps 250 Points; Scopus BioPharma Shares Spike Higher
Toward the end of trading Monday, the Dow traded up 0.75% to 34,462.98 while the NASDAQ rose 1.64% to 13,691.64. The S&P also rose, gaining 1.25% to 4,207.76. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures US Equities
Mid-Day Market Update: Crude Oil Rises 2.5%; NGM Biopharmaceuticals Shares Plunge
Midway through trading Monday, the Dow traded up 0.58% to 34,405.22 while the NASDAQ rose 1.43% to 13,663.92. The S&P also rose, gaining 1.04% to 4,199.05. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Mid-Morning Market Update: Markets Open Higher; Xeris Pharmaceuticals To Acquire Strongbridge Biopharma
Following the market opening Monday, the Dow traded up 0.50% to 34,378.59 while the NASDAQ rose 1.18% to 13,629.81. The S&P also rose, gaining 0.83% to 4,190.35. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
Strongbridge Shares Shoot Higher After Xeris' Buyout Deal At $267M
Xeris Pharmaceuticals Inc (NASDAQ: XERS) has agreed to acquire Strongbridge Biopharma plc (NASDAQ: SBBP) for stock and contingent value rights (CVRs),... 
Via Benzinga
Xeris Pharmaceuticals, Inc. to Acquire Strongbridge Biopharma plc in Stock and CVR Transaction, Creating an Innovative Leader in Endocrinology and Rare Diseases
From Xeris Pharmaceuticals, Inc.
Via Business Wire
Rule 2.5 Announcement: Xeris Pharmaceuticals, Inc. to Acquire Strongbridge Biopharma Plc in Stock and CVR Transaction, Creating an Innovative Leader in Endocrinology and Rare Diseases
From Xeris Pharmaceuticals, Inc.
Via Business Wire
Xeris Pharmaceuticals: Q1 Earnings Insights
Shares of Xeris Pharmaceuticals (NASDAQ:XERS) rose 1.8% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share increased 66.29%... 
Via Benzinga
Xeris Pharmaceuticals Reports First Quarter 2021 Financial Results and Recent Highlights
From Xeris Pharmaceuticals, Inc.
Via Business Wire
Xeris Pharmaceuticals to Webcast Upcoming Presentations
From Xeris Pharmaceuticals, Inc.
Via Business Wire
Xeris Pharmaceuticals to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 13, 2021
From Xeris Pharmaceuticals, Inc.
Via Business Wire
Earnings Scheduled For May 13, 2021
Companies Reporting Before The Bell • CASI Pharmaceuticals (NASDAQ:CASI) is estimated to report quarterly loss at $0.06 per share on revenue of $5.05 million. •... 
Via Benzinga
Xeris Pharmaceuticals Announces Extension of the Interest-Only Period of Its Debt Facility With Oxford Finance and Silicon Valley Bank
From Xeris Pharmaceuticals, Inc.
Via Business Wire
NASDAQ:XERS Shareholder Notice: Investigation over Potential Wrongdoing at Xeris Pharmaceuticals, Inc.
San Diego, CA -- (SBWIRE) -- 05/05/2021 -- Certain directors of Xeris Pharmaceuticals, Inc. are under investigation over potential breaches of fiduciary duties. 
Via SBWire
Xeris Pharmaceuticals Receives U.K. MHRA Approval of Ogluo® (glucagon) Injection for the Treatment of Severe Hypoglycaemia in Adults, Adolescents, and Children Aged 2 Years and Over With Diabetes Mellitus
From Xeris Pharmaceuticals, Inc.
Via Business Wire
With a New Diabetes Product Coming to Market, What Lies Ahead for Zealand Pharma Investors?
A new, easier-to-administer treatment for severe hypoglycemia has observers and investors wondering where its creators will go next. 
Via The Motley Fool
The Daily Biotech Pulse: Hyperphosphatemia Drug Regulatory Review Extended, Phathom Pharma Data Readout, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 29) AtriCure, Inc. (NASDAQ:... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.